Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms

Mar Drugs. 2021 Aug 27;19(9):488. doi: 10.3390/md19090488.

Abstract

Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth that harbors a great many different organisms and natural products, to identify novel drugs and drug candidates to fight against malignant neoplasms. The marine compounds show potent anticancer activity in vitro and in vivo, and relatively few drugs have been approved by the U.S. Food and Drug Administration for the treatment of metastatic malignant lymphoma, breast cancer, or Hodgkin's disease. This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives.

Keywords: anticancer; marine environment drug; mechanisms of action; natural compounds.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Biological Products* / chemistry
  • Biological Products* / pharmacology
  • Biological Products* / therapeutic use
  • Humans
  • Neoplasms / drug therapy
  • Seawater

Substances

  • Antineoplastic Agents
  • Biological Products